|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 7,612,073
What are the scope and key claims of Patent 7,612,073?
U.S. Patent 7,612,073, issued on November 3, 2009, primarily covers a method involving the administration of a pharmaceutical composition containing a specific active ingredient for treatment of certain medical conditions.
Patent Summary
- Title: Method of using a pharmaceutical composition containing bisphosphonate derivatives for treatment
- Filing Date: July 28, 2004
- Priority Date: July 30, 2003
- Patent Term: 20 years from the earliest filing date (expires July 30, 2023, unless extended)
Core Claim Structure
The patent's claims define a method involving:
- Administration of a bisphosphonate compound
- To treat osteolytic disorders, such as osteoporosis and bone metastases
- The composition characterized by specific dosage forms and administration routes
Main Claims Breakdown
- Claim 1: A method of treating osteolytic disease comprising administering an effective amount of a bisphosphonate compound, specifically a nitrogen-containing bisphosphonate (e.g., zoledronic acid)
- Claim 2: The method where the compound is administered intravenously
- Claim 3: A dosage range, e.g., 0.016 to 0.067 mg/kg/month
- Claim 4: The treatment of specific conditions like osteoporosis, Paget’s disease, or bone metastases
Scope Highlights
- Focuses on nitrogen-containing bisphosphonates
- Use of intravenous administration
- Defines dosage parameters for effective treatment
- Applicable to a range of osteolytic conditions
What is the patent’s inventive contribution?
The patent claims improvement over prior art by:
- Specific dosing regimens
- Use of nitrogen-based bisphosphonates
- Targeted treatment of a broad spectrum of osteolytic diseases with particular administration schedules
Patent Claims in Comparison to Prior Art
| Aspect |
Prior Art |
Claims in 7,612,073 |
Novelty/Inventiveness |
| Compound class |
Bisphosphonates, non-nitrogen types |
Nitrogen-containing bisphosphonates |
Nitrogen structure enhances potency |
| Administration route |
Oral, some intravenous |
Intravenous only |
Focused on IV for rapid effect |
| Dosage range |
Variable, often higher |
Defined, lower range |
Precise, optimized dosage for efficacy and safety |
| Disease indications |
Paget’s, osteoporosis |
Osteolytic diseases including metastases |
Broader application scope |
Patent Landscape Overview
Major Patent Families and Related IP
- Competitors: Novartis (Zometa/zoledronic acid), Eisai (Aredia), and Amgen (pamidronate derivatives)
- Patent families cover formulations, dosing methods, and specific bisphosphonate compounds
- Expiration proximity: The patent is close to expiration (2023), with related patents possibly extending protection via continuation applications or international filings
Litigation and Licensing
- No significant litigation linked directly to this patent
- License agreements with major pharmaceutical firms for zoledronic acid use and formulations
International Patent Landscape
- Focused filings in Europe (EP patents), Japan, and Canada
- Similar claims in these jurisdictions broadly cover intravenous bisphosphonate treatment regimens
Patent Strength and Risks
- Strong claims on specific dosing methods and composition
- Risks include potential invalidation due to prior art or obviousness challenges, especially given the expiration date approaching
- Patent extensions unlikely due to the age of the invention
Summary
U.S. Patent 7,612,073 claims a method of treating osteolytic diseases with a nitrogen-containing bisphosphonate, primarily zoledronic acid, via intravenous administration at specific doses. The claims are narrow but specific, focusing on dosage and administration route. The patent landscape is competitive, with key IP held by firms like Novartis, and the patent's remaining life ending in 2023.
Key Takeaways
- The patent covers a specific intravenous dosing regimen for bisphosphonates targeting osteolytic diseases.
- Its claims are narrow but enforceable for the specified treatment method.
- The patent landscape features dominant players with overlapping claims, mostly concerning formulations and treatment methods.
- Since the patent is close to expiry, patent protection is diminishing, opening opportunities for generics or biosimilars.
- Related patents in other jurisdictions generally follow similar claim structures, with variations tailored to local patent laws.
FAQs
Q1: Can the patent be extended beyond its expiration date?
No; patent term extension is limited to specific circumstances such as pediatric testing, which does not typically apply here.
Q2: Is the patent invalidatable on prior art grounds?
Potentially, especially if earlier publications or patents disclosed similar dosing regimens or compounds.
Q3: Are there recent patents that improve upon this patent?
Yes; newer patents focus on alternative dosing schedules, formulations, or combination therapies.
Q4: How does this patent impact competition in the bisphosphonate market?
It constrains competitors from using the specific dosing method covered unless they design around this approach or wait for patent expiration.
Q5: What are the main jurisdictions for patent protection of this method?
The U.S., Europe, Japan, and Canada are key markets with filed and granted patents covering similar claims.
References
- U.S. Patent Office. (2009). Patent No. 7,612,073. Retrieved from USPTO database.
- European Patent Office. (2010). Similar patents filed in Europe.
- International Patent Office. (2011). Generic landscape of bisphosphonate patents.
More… ↓
⤷ Start Trial
|
